Abstract:Immunotherapy is now established as a potent therapeutic paradigm engendering antitumor immune response against a wide range of malignancies and other diseases by modulating the immune system either through the stimulation or suppression of immune components such as CD4+ T cells, CD8+ T cells, B cells, monocytes, macrophages, dendritic cells, and natural killer cells. By targeting several immune checkpoint inhibitors or blockers (e.g., PD-1, PD-L1, PD-L2, CTLA-4, LAG3, and TIM-3) expressed on the surface of immune cells, several monoclonal antibodies and polyclonal antibodies have been developed and already translated clinically. In addition, natural killer cell-based, dendritic cell-based, and CAR T cell therapies have been also shown to be promising and effective immunotherapeutic approaches. In particular, CAR T cell therapy has benefited from advancements in CRISPR-Cas9 genome editing technology, allowing the generation of several modified CAR T cells with enhanced antitumor immunity. However, the emerging SARS-CoV-2 infection could hijack a patient's immune system by releasing pro-inflammatory interleukins and cytokines such as IL-1β, IL-2, IL-6, and IL-10, and IFN-γ and TNF-α, respectively, which can further promote neutrophil extravasation and the vasodilation of blood vessels. Despite the significant development of advanced immunotherapeutic technologies, after a certain period of treatment, cancer relapses due to the development of resistance to immunotherapy. Resistance may be primary (where tumor cells do not respond to the treatment), or secondary or acquired immune resistance (where tumor cells develop resistance gradually to ICIs therapy). In this context, this review aims to address the existing immunotherapeutic technologies against cancer and the resistance mechanisms against immunotherapeutic drugs, and explain the impact of COVID-19 on cancer treatment. In addition, we will discuss what will be the future implementation of these strategies against cancer drug resistance. Finally, we will emphasize the practical steps to lay the groundwork for enlightened policy for intervention and resource allocation to care for cancer patients.

Immune checkpoint therapy—current perspectives and future directions

Tumor Immune Checkpoints and Their Associated Inhibitors

A comprehensive review of immune checkpoint inhibitors for cancer treatment

The future of immune checkpoint therapy

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities

Next-generation combination approaches for immune checkpoint therapy

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Immune checkpoint blockade in hematological malignancies: current state and future potential

Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors

Immune Checkpoints in Cancers: From Signaling to the Clinic

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

[Immune-checkpoints: the new anti-cancer immunotherapies]

Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

Immune checkpoint inhibitors: recent progress and potential biomarkers

Therapeutic Development of Immune Checkpoint Inhibitors

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons